Lilly's Symbyax approved for treatment-resistant depression in US
This article was originally published in Scrip
Lilly's antidepressant Symbyax (a single capsule combination of olanzapine and fluoxetine HCl capsules) has been approved by the US FDA for the acute treatment of treatment-resistant depression, or depression that has not responded adequately to treatment with two previous attempts with antidepressants.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.